Apmonia Therapeutics announces a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP-01)
Success for Apmonia Therapeutics’ technology platform developing a portfolio of therapeutic peptides targeting tumor microenvironment in solid tumors
Press release: SATT Nord and Apmonia Therapeutics have entered into agreements in which Apmonia Therapeutics has been granted an exclusive worldwide license for the development
Apmonia Therapeutics is honored and delighted to have been elected as most promising #startup of the year during “Welcome to Reims” event last week. We
